RYR3
Ryanodine receptor 3
As of the edition of 20 October 2026, RYR3 (ryanodine receptor 3, UniProt Q15413) has 1 drug tested at it and 4 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q15413
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 10
- Disease areas
- Nervous system; Heart and blood vessels; Injuries; Ear, nose and throat; Eye; Hormones; Immune system; Inherited and neonatal
- Registered trials of its drugs
- 11
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Dantrolene | Marketed | Phase 3 | none listed |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Undetermined | 3 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Norgine | Route B |
The other 3 companies at RYR3
In the product4 companies in all; 3 are not named here, and no score is.
See the 4 companies at RYR3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.